Longevity Evidence Lab Human evidence, uncertainty intact
Research interpretation, not diagnosis or personal treatment advice. Urgent symptoms belong with a clinician, not a browser tab.
Home / Evidence / Urolithin A
Mitochondrial signalling

Urolithin A

A plausible mitophagy intervention with early functional signals, still far from longevity proof.

The 30-second verdict Urolithin A is a gut-microbial metabolite derived from ellagitannins, although many people produce little naturally. Human trials suggest it can alter mitochondrial gene-expression or biomarker patterns and may modestly improve selected muscle endurance measures. No study shows extended human life or prevention of age-related disability.

Evidence matrix

These scores describe different evidence domains. A strong mechanism cannot compensate for missing human outcomes, and a useful clinical effect need not imply slower biological ageing.

Human clinical outcomes Limited
Human biomarkers Moderate
Animal lifespan Limited
Mechanistic plausibility Moderate
Safety certainty Limited
Direct longevity relevance Preliminary

What has been shown in humans?

Randomised trials are relatively small and often industry sponsored. The most interesting findings concern mitochondrial signatures and certain endurance measures rather than large changes in strength or daily function.

What remains uncertain?

Independent replication, long-term safety, clinical importance of biomarker changes, comparative value against exercise and effects in frail populations are unresolved.

Doses used in research

Descriptive, not prescriptive Trials generally use standardised purified urolithin A rather than relying on variable food conversion. Results cannot be assumed for pomegranate or berry products.

Safety and interpretation

  • Short trials report acceptable tolerability, but long-term experience is limited.
  • Commercial evidence is closely tied to proprietary products and should be read with conflict-of-interest information visible.

Primary sources and evidence reviews

Editorial note

This dossier was last reviewed on 13 July 2026. Ratings can change when larger trials, adverse-event data or better systematic reviews appear. Corrections should alter the page rather than being buried in a social-media thread.